Vice President, Immix Biopharma, Inc.
Mr. Witt leads operations at Immix Biopharma, Inc – an oncology therapeutics firm focused on inhibiting mechanisms underlying the very nature of tumor resistance. Immix is poised to begin first-in-man studies with its lead candidate in 2017. As a volunteer, he also serves on BIOCOM’s Capital Development Committee. Previously, Mr. Witt helped high-growth startups in healthcare, backed by top venture capitalists and angel investors such as Y Combinator, Yuri Milner, 500 Startups, Rock Health, Charles River Ventures, and General Catalyst, move to their next value-inflection points. Through his efforts, products at these companies have reached tens of thousands of physicians and millions of patients across the US. Ryan has also served as a working group member at ONC/DHHS, as a patient advocate, and as a lobbyist around combination therapies and molecular medicine underpinnings (i.e., the predecessor to personalized medicine / precision oncology).
Pricing’s Looming Effect on I/O & PM
Checkpoints and I/O therapies, chemotherapy regimens and oncogenic driver targeted therapies have one result in common – a percentage of patient tumors always recur. Despite mechanisms underlying tumor resistance being known for decades, biopharma has never focused on this therapeutic class due to regulatory and reimbursement frameworks – until now.